» Articles » PMID: 33220823

Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis

Overview
Specialties Neurology
Radiology
Date 2020 Nov 22
PMID 33220823
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Radiographic monitoring of posttreatment glioblastoma is important for clinical trials and determining next steps in management. Evaluation for tumor progression is confounded by the presence of treatment-related radiographic changes, making a definitive determination less straight-forward. The purpose of this article was to describe imaging tools available for assessing treatment response in glioblastoma, as well as to highlight the definitions, pathophysiology, and imaging features typical of true progression, pseudoprogression, pseudoresponse, and radiation necrosis.

Citing Articles

An effective MRI perfusion threshold based workflow to triage additional F-FET PET in posttreatment high grade glioma.

Kadali K, Nierobisch N, Maibach F, Heesen P, Alcaide-Leon P, Hullner M Sci Rep. 2025; 15(1):7749.

PMID: 40044711 PMC: 11882894. DOI: 10.1038/s41598-025-90472-8.


Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAF glioblastoma results in sustained response: A case report.

Wagle N, Sharma A, Nguyen M, Truong J, Juarez T, Kesari S Neurooncol Adv. 2024; 6(1):vdae110.

PMID: 39036436 PMC: 11259949. DOI: 10.1093/noajnl/vdae110.


Resolving spatial response heterogeneity in glioblastoma.

Ziegenfeuter J, Delbridge C, Bernhardt D, Gempt J, Schmidt-Graf F, Hedderich D Eur J Nucl Med Mol Imaging. 2024; 51(12):3685-3695.

PMID: 38837060 PMC: 11445274. DOI: 10.1007/s00259-024-06782-y.


Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma.

Dai L, Jing Z, Zhu Y, Deng K, Ma L Am J Cancer Res. 2024; 13(12):5950-5965.

PMID: 38187045 PMC: 10767359.


Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.

Huo X, Wang Y, Ma S, Zhu S, Wang K, Ji Q Medicine (Baltimore). 2023; 102(51):e36581.

PMID: 38134061 PMC: 10735121. DOI: 10.1097/MD.0000000000036581.